BioProgress Technology Appoints Doug Miller As Senior Consultant And Lisa Cozza As Senior Director, Business Development And Strategy
Published: Oct 10, 2017
Addition of Two Seasoned Biotechnology Veterans Expands BPTC’s Capabilities
WOBURN, Mass.--(BUSINESS WIRE)--BioProcess Technology Consultants, Inc. (BPTC), the leading strategic, technical, and regulatory consulting company for the global biopharmaceutical industry, has appointed Douglas Miller, Ph.D., as a Senior Consultant and Lisa Cozza as Senior Director, Business Development and Strategy.
Dr. Miller has more than 25 years of experience in process and product development in the biotechnology industry, including both upstream and downstream process development of protein therapeutics, cell therapy process development, process scale-up and technology transfer, scientific project team leadership, manufacturing technology development, and plant-to-plant operational alignment and governance.
“As more and more of our clients seek to develop and commercialize CAR-T and other cell and gene therapy products, Doug’s expertise will provide them with a critical resource to de-risk their CMC programs and accelerate development of exciting new products with the potential to transform patient’s lives,” said Thomas C. Ransohoff, Vice President and Principal Consultant. “In addition to his cell therapy experience, Dr. Miller is an experienced leader in process development and technology transfer for protein therapeutics. We’re excited to welcome him to our team.”
Prior to joining BPTC, Dr. Miller was Head of Process Development and Platform Strategy at Juno Therapeutics, one of the leaders in the burgeoning CAR-T field. In addition to his new role at BPTC, Dr. Miller is also an assistant professor at the University of Washington in Seattle, where he teaches process development. Earlier in his career, he held positions of increasing responsibility at Genetics Institute, Immunex, and Amgen. Doug holds a Ph.D. in chemical engineering from the University of California, Berkeley.
“With the recent approval of the first CAR-T therapeutic, the age of cell therapy has truly begun,” said Dr. Miller. “This new therapeutic modality brings unique challenges, and I am eager to share my expertise as more companies enter the field.”
Lisa Cozza brings more than 30 years of scientific, operations, and business development experience in the biopharmaceutical industry. Ms. Cozza has extensive experience in negotiating client-service agreements and managing contract manufacturing alliances, including collaborations with small start-up firms, large pharmaceutical companies, and others. Most recently Ms. Cozza served as Senior Director, External Supply Bio-Operations at AstraZeneca where she managed external biologics supply operations, oversaw multiple contract manufacturing production facilities, and was responsible for commercial launch preparation. Before AstraZeneca, Lisa was Vice President of Business Development for Laureate BioPharma, now Patheon.
Ms. Cozza has also worked at Human Genome Sciences (HGS) and Lonza Biologics where she was accountable for the commercial and clinical manufacturing, training and process technology teams. During her tenure at HGS and Lonza, Ms. Cozza held positions of increasing responsibility where she led manufacturing operations in both mammalian cell culture and microbial fermentation, built a contract services business, and implemented lean manufacturing initiatives. Before joining Lonza, she spent seven years with Genetics Institute (now Pfizer) in various tactical and lead roles in the QC labs, purification process development and clinical manufacturing areas.
“Lisa brings an impressive track record of success in operations and business development roles at life science companies of all sizes,” said Howard L. Levine, Ph.D., President and CEO of BPTC. “As our business continues to grow and expand, having an experienced senior executive with a proven track record of working closely with senior management teams in the biotechnology industry to achieve business and sales objectives make her ideally suited for our team. Her fresh perspective and analytical approach will help us effectively serve our growing client base and expand our consulting services,” added Dr. Levine.
“During my professional career, I have faced many of the same challenges confronting BPTC’s clients,” said Ms. Cozza. “I’ve seen what works and what doesn’t. I look forward to working closely with the BPTC senior management team to finalize and implement our long-term strategic plan and ensure that we continue providing the best possible solutions to our client’s needs for technical, quality, and regulatory support.”
About BioProcess Technology Consultants, Inc.
Founded in 1994, BioProcess Technology Consultants is the recognized worldwide leader in biologics Chemistry, Manufacturing, and Controls (CMC) consulting, providing a full range of technical, regulatory, and strategic assistance to pharmaceutical and biotechnology companies in the development and commercialization of biopharmaceutical products. The company works with clients globally to find and apply solutions to the challenges of biopharmaceutical product development from clone to commercial®. BPTC helps develop manufacturing processes and strategies that enhance the overall value of client companies and accelerate the advancement of new products from clone to clinic®. BPTC also helps investors make informed decisions by providing technical and business evaluations of new products and technologies and product discovery, development, and commercialization plans of potential investments and existing portfolio companies. For more information about BPTC, visit http://www.bptc.com. Follow us on Twitter at @bptcGlobal and LinkedIn at https://www.linkedin.com/company-beta/510782.
BioProcess Technology Consultants, Inc.
Al Doig, 781-281-1869